

Wood Mark

Form 3

February 08, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Wood Mark

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

06/07/2007

3. Issuer Name **and** Ticker or Trading Symbol

BIOMARIN PHARMACEUTICAL INC [BMRN]

4. Relationship of Reporting
Person(s) to Issuer

5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

____ Director ____ 10% Owner

☒ Officer ____ Other
(give title below) (specify below)

VP, Human Resources

C/O BIOMARIN
PHARMACEUTICAL
INC.,Â 105 DIGITAL DRIVE

(Street)

NOVATO,Â CAÂ 94949

(City)

(State)

(Zip)

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
____ Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative
Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

Date Exercisable Expiration
Date

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title Amount or
Number of

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: Wood Mark - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (right to buy) <u>(6)</u>	11/03/2004 ⁽¹⁾	05/02/2014	Common Stock	6,255	\$ 6.37	D	Â
Stock Option (right to buy) <u>(6)</u>	07/07/2005 ⁽²⁾	01/06/2015	Common Stock	3,553	\$ 6.13	D	Â
Stock Option (right to buy) <u>(6)</u>	07/06/2006 ⁽³⁾	01/05/2016	Common Stock	16,674	\$ 11.74	D	Â
Stock Option (right to buy) <u>(6)</u>	12/21/2006 ⁽⁴⁾	06/20/2016	Common Stock	15,000	\$ 17.54	D	Â
Stock Option (right to buy) <u>(6)</u>	05/20/2007 ⁽⁵⁾	11/19/2016	Common Stock	40,000	\$ 17.54	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wood Mark C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	Â	Â	Â VP, Human Resources	Â

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact

__**Signature of Reporting Person

Date _____

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vested 6/48ths on 11/3/2004 and 1/48th on the 3rd of each month thereafter.
- (2) Options vested 6/48ths on 7/7/2005 and 1/48th on the 7th of each month thereafter.
- (3) Options vested 6/48ths on 7/6/2006 and 1/48th on the 6th of each month thereafter.
- (4) Options vested 6/48ths on 12/21/2006 and 1/48th on the 21st of each month thereafter.
- (5) Options vested 6/48ths on 5/20/2007 and 1/48th on the 20th of each month thereafter.

(6) Mark Wood became a reporting officer on June 7, 2007. His Form 3 was inadvertently not filed at that time, but all necessary Form 4 filings have been filed since then and the information contained in this Form 3 is subject to further disclosures in the previously filed Forms 4 and all subsequent Section 16 filings.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.